Saol Therapeutics
Business Services · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1000 Holcomb Woods Pkwy Ste 270, Roswell...Phone Number
(770) 274-2476Website
www.saolrx.comRevenue
$18 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Saol Therapeutics
Saol Therapeutics is a clinical-stage pharmaceutical company focused on late-stage development of novel therapies for CNS disorders, including pain, spasticity, and orphan diseases. With operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda, the company aims to address significant unmet medical needs. Saol is guided by a team of experienced entrepreneurs and values strategic partnerships with clinicians, scientists, and biopharmaceutical companies. The company is committed to advancing the standard of care through innovative technologies applicable to multiple indications.Explore more
Saol Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Saol Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Saol Therapeutics is spiking on competitors!
Earning: See what the market has to say on Saol Therapeutics recently announced quarterly report
Check if Saol Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Saol Therapeutics
Product Launch: Get notified when Saol Therapeutics launches new products
Saol Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Saol Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Saol Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Saol Therapeutics
Find 3 more new buyers
Compare Similar Companies to Saol Therapeutics
Compare insights from companies similar to Saol Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Saol Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Saol Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Saol Therapeutics.
Saol Therapeutics financials insights
Gather financial insights about Saol Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
Saol Therapeutics Tech Stack
A closer look at the technologies used by Saol Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events
Funding
Saol Therapeutics has received an SBA PPP loan for $1-2 million from Capital One.
Funding
Saol Therapeutics News & Media
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Existing data supports direct path to resubmission following constructive FDA engagement ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, July 7, 2026 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug...Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)
FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 9, 2025 /PRNewswire/ -- Saol Therapeutics, a...Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD)
Saol is seeking a path forward with the FDA that does not require an additional trial ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug...Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference
Key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency (PDCD) were presented. ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, June 19, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Saol Therapeutics
Sign Up For FreeTo access detailed company insights
Saol Therapeutics is a clinical-stage pharmaceutical company focused on late-stage development of novel therapies for CNS disorders, including pain, spasticity, and orphan diseases. With operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda, the company aims to address significant unmet medical needs. Saol is guided by a team of experie... Read More
